News

The marketing of FatigFix is a collaboration between Chrysalis and the technology holder Phynova Group, a UK company developing prescription as well as OTC drugs for healthcare and

The study revealed that patients receiving Firazyr experienced significantly faster time to onset of symptom relief from HAE symptoms, compared to those receiving placebo. Firazyr provided a highly

Daiichi Sankyo said that the Engage AF-TIMI 48 study began enrollment in November 2008. The Phase III Engage AF-TIMI 48 clinical study is an event-driven, randomised, double-blind, double-dummy,

Ulipristal acetate is an orally active selective progesterone receptor modulator that reversibly blocks the progesterone receptors in targeted tissues. HRA Pharma has been developing ulipristal acetate for a

Global Health said Relax-B is the sublingual formulation of Propranolol currently marketed for hypertension and it has decided to develop a rapid absorption formulation using their proprietary sublingual

AMT and Amgen claim that the GDNF gene contains the information to produce a protein necessary for the development and survival of nerve cells. According to AMT, the

Specifically, the Therapex Division of E-Z-EM Canada, a wholly-owned subsidiary of Bracco Pharma in Italy, will manufacture the product for Apricus Bio. Apricus said Therapex will also be

Nanjing MeiRui is the operating entity of Pagoda Pharma Group, a British Virgin Islands-based holding company that established the Chinese health-care company in 1996. Branded drugmakers, including GSK,

The UK drug maker acquired SRT501, a proprietary formulation of resveratrol, a substance found in grapes and red wine, from biotech company Sirtris Pharmaceuticals, as part of the